These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29865869)

  • 21. Updated NACI recommendations for measles post-exposure prophylaxis.
    Tunis MC; Salvadori MI; Dubey V; Baclic O;
    Can Commun Dis Rep; 2018 Sep; 44(9):226-230. PubMed ID: 31015814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next.
    Young MK; Cripps AW
    Hum Vaccin Immunother; 2013 Sep; 9(9):1885-93. PubMed ID: 23783220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
    Buxbaum S; Doerr HW; Allwinn R
    Dtsch Med Wochenschr; 2001 Nov; 126(46):1289-93. PubMed ID: 11709730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
    Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
    J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cytostatic therapy reduces the immune defense. Children treated for leukemia have impaired immunity against measles and rubella].
    Nilsson A; Nordin M; De Milito A; Grillner L; Chiodi F; Björk O
    Lakartidningen; 2000 Nov; 97(45):5116-8. PubMed ID: 11116890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
    Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
    Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Australian population cohort study of newly arrived refugee children: how effective is predeparture measles and rubella vaccination?
    Joshua PR; Smith MM; Koh AS; Woodland LA; Zwi K
    Pediatr Infect Dis J; 2013 Feb; 32(2):104-9. PubMed ID: 22955722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-rubella, Mumps and Measles IgG Antibodies in Medical Students of Tehran University.
    Keshavarz M; Nicknam MH; Tebyanian M; Shahkarami MK; Izad M
    Iran J Allergy Asthma Immunol; 2016 Jun; 15(3):244-50. PubMed ID: 27424140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
    J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Post-exposure prophylaxis against measles].
    Følsgaard NV; Nygaard U; Christiansen CB; Harder KM; Andersen PH; Poulsen A
    Ugeskr Laeger; 2015 Nov; 177(48):V06150467. PubMed ID: 26617173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
    Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
    Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of hepatitis B markers and measles, mumps, and rubella antibodies among Jewish refugees from the former Soviet Union.
    Hurie MB; Gennis MA; Hernandez LV; Dindzans VJ; Davis JP
    JAMA; 1995 Mar 22-29; 273(12):954-6. PubMed ID: 7884955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
    Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
    Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study.
    Heijstek MW; van Gageldonk PG; Berbers GA; Wulffraat NM
    Ann Rheum Dis; 2012 Jun; 71(6):948-54. PubMed ID: 22172491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.